Choosing among the incretin agents and why it matters.
Unger
Jeff
J
Loma Linda University School of Medicine, Loma Linda, California, USA.
D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000502:physiology; D008055:Lipids / Q000097:blood; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use; D015431:Weight Loss
D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D008055:Lipids; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; C502994:saxagliptin; D000077270:Exenatide; D000218:Adamantane; D000068900:Sitagliptin Phosphate